In addition to the one-time, upfront payment, UCB will also receive royalties for a period of five years based on sales and a standard manufacturing supply agreement with a ‘cost-plus’ structure.
“This transaction is another step taken by UCB in its strategy to focus on research-driven innovation and novel therapeutic solutions for severe and chronic diseases treated by specialist physicians,” said Roch Doliveux, CEO of UCB.
Delsym is made with a patented time-release formulation that allows the cough suppressant dextromethorphan to be available in the body over a 12-hour period.
The companies also announced that they have entered into a separate agreement for the licensing of the 12-hour liquid technology.